Knight Therapeutics (TSE:GUD) Reaches New 1-Year High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD)’s stock price reached a new 52-week high during mid-day trading on Thursday. The company traded as high as C$11.71 and last traded at C$11.70, with a volume of 70,523 shares. The stock had previously closed at C$11.45.

Knight Therapeutics Stock Performance

The stock has a market capitalization of C$1.14 billion, a PE ratio of 77.40, a PEG ratio of -1,013.50 and a beta of -0.45. The business’s 50 day moving average is C$10.28 and its 200 day moving average is C$9.35. The company has a current ratio of 2.28, a quick ratio of 1.79 and a debt-to-equity ratio of 4.29.

Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, August 6th. The company reported C($0.03) EPS for the quarter. The business had revenue of C$143.97 million for the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. On average, equities research analysts predict that Knight Therapeutics Inc. will post 0.10 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.